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Abstract
Background: Elevated plasma counts of endothelial microparticles (MP) have been demonstrated
in various diseases with a vascular injury component. We used flow cytometry to study the MP-
release from cultured human umbilical vein endothelial cells (HUVEC) stimulated by various
agonists. MP-release by a topoisomerase I inhibitor camptothecin has been studied in detail.
Results: Overnight stimulation of HUVEC with either LPS or TNFα , or 30 min stimulation with
thrombin, phorbol-myristate-acetate, tissue plasminogen activator, or angiotensin-II did not cause
a significant release of annexin V-binding MP. In contrast, induction of apoptosis with 5 µM
camptothecin, documented by 60–70% desquamation of HUVEC culture, annexin V-binding to the
cells and DNA-fragmentation, led to a release of annexin V-binding microparticles (~80,000 MP/
103 cells). This microparticle-release was prevented by Z-Val-Ala-Asp-fluoromethyl-ketone
(ZVAD). Lower concentration of camptothecin (500 nM) induced comparable microparticle-
release without loss of the culture confluence and without increase in annexin V-binding to the cells
or DNA-fragmentation. Analyzed microparticles were free of nucleic acids and 95% of
microparticles were 0.3–1 µm in size. Double-labeling flow cytometry assay showed that all annexin
V-binding Microparticles expressed CD59 but only approximately 50% of these also expressed
CD105.
Conclusions: Camptothecin treated HUVEC released different populations of annexin V-binding
membrane microparticles at early stage after proapoptotic stimulation before detection of
phosphatidylserine exposure on the cells or DNA fragmentation. The microparticle-release was
ZVAD sensitive but was not enhanced at the executive phase of apoptosis. These observations
offer a new insight into microparticle-release as a marker of endothelial stimulation and injury.
Background
Plasma membrane microparticles (MP) of endothelial or-
igin have been identified in normal human blood [1–3]
and increased counts of MP carrying endothelial antigens
were documented in the blood of patients with lupus an-
ticoagulant [1], acute coronary syndrome [4], thrombotic
thrombocytopenic purpura [5] or in patients with exacer-
bated multiple sclerosis [6]. Similarly to blood platelets,
endothelial cells release MP which express phosphatidyl-
serine (PS) on their surface. PS-exposing MP in blood ap-
pear to act as the catalytic surface for assembly of the
prothrombinase complex [7]. Although circulating MP of
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various cellular origin in patient with sepsis were reported
to be procoagulant through multiple mechanisms [8,9],
in healthy individuals they may have an anticoagulant
function by promoting the generation of low amounts of
thrombin that activate protein C [2].
The process of membrane vesiculation and MP-release in
platelets has been shown to require a calpain-dependent
dissociation of membrane proteins from the submem-
brane cytoskeleton and most likely involves intracellular
signaling by platelet protein kinases [10]. Besides platelets
stimulated by various agonists such as thrombin with col-
lagen or the complement complex C5b-9 [7,11], a release
of PS-containing membrane MP was demonstrated in oth-
er cell types such as endotoxin-stimulated monocytes
[12], polymorphonuclear leucocytes stimulated with the
chemotactic peptide FMLP [13] or apoptotic T-lym-
phocytes [14]. The normal restriction of PS to the inner
surface of the plasma membrane becomes perturbed in
apoptotic cells [15,16]. When exposed, PS is a determi-
nant for phagocyte recognition of cells to be cleared. Plas-
ma membrane blebbing and MP-release are generally
accepted as typical signs of cell apoptosis [17].
In addition to a possible pathophysiological role of circu-
lating MP, analysis of MP derived from endothelial cells
may be a valuable diagnostic marker of vessel wall injury.
The phospholipid-binding protein annexin V has a high
affinity for PS [18] and is utilized in MP detection in
blood and in cell supernatants [1]. Since very little is
known about the mechanism of MP-release from en-
dothelial cell, it is difficult to judge the type and extent of
endothelial injury represented by increased plasma
counts of endothelial MP. We used flow cytometry to
study the release of annexin V-binding membrane micro-
particles from cultured human umbilical vein endothelial
cell (HUVEC) stimulated by various agonists. We further
focused our study on MP-release from HUVEC after proa-
poptotic stimulation with the topoisomerase I inhibitor
camptothecin (CPT). Since CPT analogues become one of
the most promising new classes of antineoplastic agents
introduced into the clinic in recent years [19], activity of
camptothecin on endothelial cells may be of great inter-
est.
Results
With the exception of high concentration of ionophore 
A23187, rapid stimulation of HUVEC with various agonists 
did not result in a release of annexin V-binding microparti-
cles
Flow cytometry analysis of HUVEC culture supernatant
demonstrated that a 30 min treatment with 10 µM iono-
phore A23187 caused the release of low counts of annexin
V-binding MP (Fig. 1A). Similar short-time activation of
HUVEC with phorbol myristate acetate (PMA) (1 µg/mL),
human thrombin receptor activating peptide (TRAP) 1–
50 µmol/L, human thrombin (THR) 0.1–10 NIH Unit/
mL, human tissue plasminogen activator (TPA) 3.5 kU/
mL or human angiotensin II (AGTII) 1 µmol/L did not
cause any significant increase in MP-release (Fig. 1A). All
of the agonists applied induced morphological changes in
HUVEC seen by phase contrast light microscopy, which
confirmed the cellular activation (not shown).
Proapoptotic, but not proinflammatory, stimulation in-
duced a release of annexin V-binding microparticles from 
HUVEC
MP count increased overnight in the media of unstimulat-
ed cell culture, but this was not enhanced by TNFα  (1000
U/ mL) or by LPS (10 µg/mL). However, when cells were
activated with TNFα  in the presence of cycloheximide (50
µg/mL) to promote apoptosis [20], a dramatic increase in
MP count was observed, as compared to TNFα  or cy-
cloheximide treatment alone (Fig. 1B). Similarly, induc-
tion of apoptosis with 5 µM CPT, a topoisomerase I
inhibitor [19], led to a release of annexin V-binding MP
which was prevented by ZVAD. ZVAD also inhibited a re-
lease of MP from unstimulated cells, which probably rep-
resents spontaneous apoptosis of cultured HUVEC (Fig.
1B).
MP-release did not correlate with the level of cell apopto-
sis in HUVEC stimulated with camptothecin
Phase contrast microscopy showed that HUVEC culture
treated for 24 hrs with 5 µM CPT (Fig. 2C) lost confluence
with about 30–40% cells remaining adherent. The level of
apoptosis of adherent cells was assessed by using TUNEL
and annexin V-FITC/ propidium iodide assays (Fig 3). Ap-
proximately one third of the remaining adherent cells
showed annexin V-binding (Fig. 3B) and DNA-fragmenta-
tion (TUNEL-positivity) (Fig. 3C). Interestingly, a ten
times lower concentration of CPT (500 nM) also induced
significant MP-release after only 4 hrs of treatment (Fig.
3A) and after 24 hrs, 500 nM camptothecin induced MP-
release comparable to 5 µM CPT treatment, but without
any significant increase in annexin V-binding to the cells
or DNA-fragmentation (Fig. 3B,3C). The cell culture was
still confluent (Fig. 2B) with about 20–30% lower cell
density as compared with 0.5% DMSO treated HUVEC
(Fig. 2A). This result indicates that MP-release is not relat-
ed to cell desquamation. To investigate whether matura-
tion of the cell culture influences the degree of MP-release
from HUVEC in response to CPT, we compared MP-re-
lease from subconfluent HUVEC (50% of confluence) at
24 hrs in culture, HUVEC reaching confluence at 48 hrs in
culture and overgrown HUVEC at 72 hrs in culture. Our
results showed that MP-release in response to CPT de-
clined with culture maturation. There was also a change of
the sensitivity of overgrown HUVEC to CPT treatment in
confluent 72 hrs old culture resulting in the higher con-BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/11
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centration of CPT (5 µM) releasing higher levels of MP
(Fig. 4). In growing culture at 24 hrs, 500 nM CPT caused
even higher MP-release than 5 µM CPT. In confluent HU-
VEC 48 hrs old, the MP-release induced by 500 nM and 5
µM CPT was not significantly different (Fig. 4).
Endothelial antigens CD 105 and CD 59 were both ex-
pressed on living cells, apoptotic bodies and other cell frag-
ments in CPT treated HUVEC culture but CD 105 was 
absent on 50% of annexin V-binding membrane micropar-
ticles
Using flow cytometry, in SSC vs. FSC plot we gated homo-
geneous population of single living cells (G1 on Fig. 5A),
which appeared negative in propidium iodide staining
(Fig. 5B). Living cells from control cultures as well as from
cultures treated with CPT were strongly positive for both
antigens CD 105 and CD 59 (Fig. 5C). Expression of
CD59 on endothelial cells was not influenced by 24 hrs
incubation with 500nM or 5µM CPT as compared with
control cells incubated with 0.5% DMSO. Expression of
CD105 was only slightly decreased on CPT treated cells.
Cell fragments > 4 µm in size as compared with standard
beads were gated separately (G2 on Fig. 5A). Larger cell
fragments appeared positive in propidium iodide staining
(Fig. 5B). All analyzed cell fragments were positive for
CD59 and also expressed CD 105 (Fig. 5D). Comparison
of areas under the different peaks on the histogram (Fig.
5C,5D) indicates that the portion of cell fragments corre-
sponding to apoptotic bodies and necrotic cells was sig-
nificantly higher in culture treated with 5 µM CPT as
compared to culture treated with 500 nM CPT or with
0.5% DMSO alone. In a separate protocol we analyzed the
expression of CD 59 and CD 105 on membrane MP.
Comparison of FSC values of standard beads and ana-
lyzed MP showed that 95% of annexin V-binding MP re-
leased from HUVEC were < 1 µm in size (range 0.3 – 3.0
µm). Analyzed MP were free of nucleic acids as they were
not stained with propidium iodide (not shown). Double-
labeling flow cytometry assay showed that all annexin V-
binding membrane MP expressed CD59 but only approx-
imately 50% of these expressed CD 105 (Fig. 6).
Discussion
Our previous study demonstrated that cultured HUVEC
released annexin V-binding membrane MP in response to
proapoptotic stimulation with CPT [3]. In the present
study, we investigated whether endothelial cells release
membrane MP after rapid stimulation with Ca2+-mobiliz-
ing agents or after overnight stimulation with proinflam-
matory agents TNFα  and LPS, or only after induction of
apoptosis. Our negative results with thrombin, TRAP,
PMA, TPA and AGTII indicate that rapid Ca2+-mobiliza-
tion, despite dramatic morphological changes of the cells,
does not result in MP-release from HUVEC (Fig. 1A). The
only report showing MP-release after rapid stimulation
Figure 1
Release of annexin V-binding microparticles from
HUVEC after stimulation with different agonistsA)
Short-time stimulation (30 min): confluent HUVEC at
48 hrs in culture were incubated with buffer HBSS/BSA only
(HBSS), 0.5 % DMSO in HBSS/BSA (DMSO), 10 µM A23187
(A23187), PMA 1 µg/mL (PMA), 10 µM thrombin receptor
activating peptide (TRAP), thrombin 1 NIH U/mL (THR), tPA
3.5 kU/mL (TPA), or with 1 µM angiotensin II (AGTII). B)
Overnight stimulation (24 hrs): confluent HUVEC at 48
hrs in culture were incubated with medium only (MEDIUM),
0.5 % DMSO in medium (DMSO), TNFα  1000 U/mL (TNF),
cycloheximide 50 µg/mL (CHX), TNFα  1000 U/mL with
cycloheximide 50 µg/mL (TNF/CHX), lipopolysaccharide E.
coli 055:B5 10 µg/mL (LPS), 5 µM camptothecin (CPT), 5 µM
camptothecin with 50 µM Z-VAD-fluoromethyl ketone
(CPT/ZVAD), or with 50 µM Z-VAD-fluoromethyl ketone.
After incubation, supernatant from cell culture was harvested
and annexin V-FITC-positive MP were counted. Means of 4
independent experiments ± SD are presented, * = p < 0.05
vs. DMSO (ANOVA).
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Figure 2
Phase contrast photomicrographs of HUVEC culture
after treatment with camptothecin Confluent HUVEC
at 48 hrs in culture were treated for 24 hrs with (A) 0.5 %
DMSO: confluent culture, (B) 500 nM CPT: confluent culture
with about 20–30% lower cell density as compared with A ;
(C) 5 µM CPT : apoptotic culture with about 60–70 % desq-
uamation, bright objects represent floating cell fragments
including apoptotic bodies. Phase contrast photomicrographs
(200 × ) are shown.
A
20 µm
B
20 µm
C
20 µm
Figure 3
Release of annexin V-binding membrane microparti-
cles and the level of cell apoptosis in HUVEC stimu-
lated with camptothecin. Confluent HUVEC at 48 hrs in
culture were incubated with 0.5 % DMSO or with 500 nM or
5 µM CPT in medium. After indicated time periods superna-
tant from cell culture was harvested and annexin V-FITC-
positive MP were counted (A). Adherent cells were har-
vested and portions of cells binding annexin V (propidium
iodide negative) (B) and portions of TUNEL-positive cells (C)
were evaluated. Means of 4 experiments ± SD are presented,
* = p < 0.05 vs. DMSO (ANOVA).
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with a physiologic agonist is the study by Hamilton et al.
[21] that demonstrated MP-release from HUVEC with the
complement complex C5b-9. This membrane-attack com-
plex may destabilize cell membrane by generating pores
in phospholipid bilayer. We observed MP-release from
HUVEC after short-time treatment only with high concen-
trations (10 µM) of A23187. In this experiment, a direct
destabilizing effect of the Ca2+-ionophore A23187 on cell
membrane resulting in MP formation is also likely. An-
other question is relation of plasma membrane blebbing
and MP-release. One study documented peroxide-in-
duced membrane blebbing after a short time stimulation
of endothelial cells [22]. Although MP-release was not in-
vestigated, authors showed micrographs of stimulated
cells with membrane blebs of about 3 µm in diameter.
Size of majority of MP produced in our experiments is less
than 1µm. This difference indicates that the mechanism of
MP-release may be different from membrane blebbing vis-
ually observed on cells by conventional light microscopy.
We did not find any significant MP-release from HUVEC
after overnight stimulation with TNFα  (Fig. 1B) although
stimulation of the HUVEC culture was confirmed by up-
regulation of CD 54 on cell surface (not shown). In com-
parison, Combes et al. [1] recorded a four fold increase in
MP count in HUVEC culture stimulated overnight with
TNFα  when compared to control cells. These discrepant
results may stem from differences in HUVEC culture con-
ditions and the flow cytometric assay. In our study, the
proapoptotic stimulation was the only efficient way to re-
lease membrane MP from HUVEC. Since MP-release from
endothelial cells after proapoptotic stimulation was not
studied before, we focused on its characterization. We
used CPT, an inhibitor of topoisomerase I, that is a well
defined apoptogenic agent belonging to a promising class
of antineoplastic drugs [23]. In contrast to more physio-
logical stimuli (i.e, oxidative stress) induction of apopto-
sis by CPT is less complex and thus is a better model for
study of MP-release phenomenon. Our results showed
that the growth stage of HUVEC culture influenced MP re-
lease in response to CPT (Fig. 4). It is difficult to under-
stand why 500 nM CPT caused higher MP-release than 5
µM CPT in subconfluent HUVEC. This difference is small
and may be influenced by error of analysis. It is evident,
however, that cell culture maturation increased resistance
to camptothecin treatment. This may be related to de-
creased DNA synthesis in mature confluent HUVEC.
Size distribution of annexin V-binding MP released from
HUVEC after proapoptotic stimulation was similar to that
of endothelial MP found in blood [1]. The small size and
the absence of nucleic acids indicate that the analyzed MP
are different from apoptotic bodies formed in the termi-
nal stage of apoptosis. Our finding of CD59+ CD105+
and CD59+CD105- populations of MP (Fig. 6) suggests
that HUVEC can release different types of annexin V-bind-
ing MP with respect to their antigen expression. This ob-
servation cautions against the use of a single antigen for
detection of endothelial MP in blood. The presence of
CD59 on all annexin V-binding MP corresponds to the
high expression of this glycosylphosphatidylinositol an-
chored glycoprotein on endothelial cells. The ho-
modimeric transmembrane glycoprotein CD 105
(endoglin) is relatively specific for endothelial cells and is
abundant with more than 500,000 copies per cell on HU-
VEC [24]. It is not clear, however, why they are CD59-pos-
itive MP that express CD105 and some that do not (Fig.
6). Although CD 105 was shown to be an endothelial cell
proliferation marker [25], its expression was only slightly
decreased on CPT treated cells (Fig. 5C) and was stable on
overgrown confluent HUVEC up to 96 hrs in culture (not
shown). We also found this antigen on cell fragments, in-
cluding apoptotic bodies (Fig. 5D). Since CD59 is a pro-
tein with an important complement regulatory function,
and CD105 is a component of the receptor for TGFβ , there
may be functional and/or diagnostic differences in the MP
populations.
Figure 4
Release of annexin V-binding membrane microparti-
cles in subconfluent, confluent and overgrown
HUVEC culture treated with camptothecin HUVEC at
24 hrs (50% of confluence), 48 hrs (reaching confluence) or
72 hrs (overgrown) in culture were incubated for 24 hrs with
0.5 % DMSO, 500 nM or 5 µM CPT in medium. After incuba-
tion supernatant from cell culture was harvested and annexin
V-FITC-binding MP were counted. Means of 4 experiments ±
SD are presented, significant differences (p < 0.05, ANOVA):
500 nM CPT – 24 hrs vs. 48 hrs, 48 hrs vs. 72 hrs, 24 hrs vs.
72 hrs; 5 µM CPT – 24 hrs vs. 48 hrs, 24 hrs vs. 72 hrs; 24
hrs – 500 nM CPT vs. 5 µM CPT; 72 hrs – 500 nM CPT vs. 5
µM CPT.
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Figure 5
Expression of CD59 and CD105 on endothelial cells and apoptotic bodies in HUVEC culture treated with
camptothecin Confluent HUVEC at 48 hrs in culture were treated for 24 hrs with 0.5% DMSO, 500 nM or 5 µM CPT in
medium. After treatment the cell culture supernatant was pooled with harvested adherent cells. Mixture of cells, apoptotic
bodies and other cell fragments was labeled with propidium iodide (PI) or with PE-labeled Mabs to CD59 or CD105 and ana-
lyzed by flow cytometry. Forward scatter (FSC) vs. side scatter (SSC) plot (A) shows gated intact single cells (G1) and apop-
totic bodies and other cell fragments (G2) in a sample treated with 0.5% DMSO alone. PI – fluorescence vs. FSC plots of this
sample is shown (B). Histograms showing expression of CD105 and CD59 on cells (C) and cell fragments (D) from HUVEC
treated with 0.5% DMSO (solid line), 500 nM CPT (dotted line) or 5 µM CPT (dashed line) are shown. Binding of the IgG2a
isotype control (IgG-IC) corresponded to the fluorescence of nonlabeled cells and cell fragments. Results are representative of
three experiments.
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It is generally accepted that appearance of PS on the out-
side of the plasma membrane is an early sign of apoptosis
in many cell types after different treatments [26]. Chan et
al[27] showed that exposure of PS on the cell surface pre-
ceded DNA strand breaks in apoptosis of different cell
lines. Cell membrane vesiculation and release of MP is
considered to belong to the execution stage of apoptosis
where the fate of the cell is sealed. To our surprise, in CPT
treated HUVEC the MP-release did not correlate with the
extent cell desquamation and apoptosis or remaining ad-
herent cells characterized by PS exposure on the cell mem-
brane and DNA-fragmentation (TUNEL) (Fig. 3). In
contrast, Aupeix et al. [17] reported that the release of PS-
containing MP was proportional to hypodiploid DNA in
THP-1 and U-937 cells stimulated by various apoptotic
agents. Our experiments with 500 nM CPT treated HU-
VEC indicate that annexin V-binding MP may be released
from adherent cells at initial phase of apoptosis before ex-
posure of PS on cell surface or DNA fragmentation. Cell
desquamation and massive formation of apoptotic bodies
seen after 5 µM CPT treatment did not further enhance the
MP-release (Fig. 3) thus supporting the hypothesis that
annexin V-binding MP-release takes place in the initial
phase of apoptosis. The essential step in plasma mem-
brane destabilization and MP-release very likely is a cas-
pase-dependent sphingomyelin hydrolysis, which leads to
the production of ceramide [28–30]. It is possible, howev-
er, that sphingomyelin hydrolysis and MP-release may be
a consequence of the action of initiator caspases or other
ZVAD sensitive proteases rather than only executioner cas-
pases [15,31,32]. Our study was performed in HUVEC
culture, which may have particular properties in respect of
MP release when compared with endothelial cells from
other organs. Our finding that the PS is not exposed on
the cells treated with low concentration of CPT while they
release PS-containing MP may suggests that these cells re-
lease MP to remove PS from the cell surface as a protective
mechanism that may counteract proapoptotic stimulation
in the life/death decision process.
Conclusions
Our results demonstrate that HUVEC release different
populations of annexin V-binding membrane MP in re-
sponse to proapoptotic stimulation. We showed that rap-
id stimulation of HUVEC with thrombin, PMA, TPA or
AGT II or overnight stimulation with TNFα  or LPS does
not induce release of annexin V-binding membrane MP.
Release of MP after treatment with camptothecin very like-
ly occurs at early stage prior to a "point of no return" in
apoptosis. This phenomenon may represent a physiologic
repair process rather then be a part of apoptotic cell death.
Materials and methods
Monoclonal antibodies
Phycoerythrin (PE) conjugated IgG2a isotype control
(IgG-IC) was obtained from Immunotech, (Marseille,
France). Mab to human CD59 (PE-conjugated, clone
MEM 43) was from Caltag Lab. (Burlingame, CA), Mab to
Figure 6
Expression of CD59 and CD105 on annexin V-binding
HUVEC microparticles. HUVEC at 48 hrs in culture
were incubated for 24 hrs with 5 µM CPT. After incubation
MP in culture medium were harvested and double-labeled
with annexin V-FITC and a saturating concentration of a PE-
conjugated Mab : IgG2a isotype control (IgG-IC, filled area),
binding of the isotype control corresponded to the fluores-
cence of nonlabeled MP; Mab to CD59 (dashed line); Mab to
CD105 (thick line). After incubation and washing, samples
were analyzed by flow cytometry. The annexin V-FITC posi-
tive MP were gated in R1 gate in FITC-flourescence vs. SSC
plot (A) and their binding of PE-labeled Mabs was evaluated
in PE-fluorescence histogram plot (B). Results are represent-
ative of six experiments.
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human CD105 (PE-conjugated, clone N1-3A1) was from
Ancell/Alexis (San Diego, CA).
Endothelial cell culture
HUVEC were obtained from Clonetics (San Diego, CA)
and cultured in endothelial cell growth media EGM-2
(Clonetics) containing 2% of fetal bovine serum and sup-
plements. Cells of 2nd passage were used in the experi-
ments. Cells were seeded at a density of 10,000 cells/cm2
in polystyrene Falcon six-well plates or 60 mm dishes
(Becton Dickinson Labware, Franklin Lakes, NJ) and
maintained at 37°C under an atmosphere of 5% of CO2
and 95% room air. Cells were used for experiments at 48
hrs in culture when they reached confluence. For apoptot-
ic assays, treated culture was washed with Hanks' bal-
anced salt solution (HBSS) with 0.35% bovine serum
albumin (HBSS/BSA) and adherent cells were harvested
with 20 mM HEPES buffer with 100 mM NaCl, 0.5% BSA
and 10 mM EDTA, pH 7.4. After harvest, cells were centri-
fuged (300 g/5 min), washed with HBSS/BSA and used for
analysis.
Phase contrast microscopy
HUVEC cultures in 6-well plates were photographed using
CK40 Olympus culture microscope (Olympus, Japan)
with a SPOT camera and software (Diagnostic Instru-
ments, Inc., MI, USA). Phase contrast at 200×  magnifica-
tion was used. The culture cell density was estimated by
visual counting of cells in a standard area on the micro-
graphs.
Overnight stimulation of HUVEC
Confluent HUVEC were washed with HBSS and incubated
for 24 hrs at 37°C with various agonists in the medium:
MEDIUM only; DMSO 0.5 % (vehicle for camptothecin);
tumor necrosis factor-α  (TNF) from Alexis Biochemicals
(San Diego, CA) 100 or 1000 U/mL; cycloheximide
(CHX) 50 µg/mL; TNF 1000 U/mL with cycloheximide 50
µg/mL (TNF/CHX); lipopolysaccharide (LPS) E. coli
055:B5 from Calbiochem (San Diego, CA) 10 µg/mL;
camptothecin (CPT) from Sigma (St. Louis, MO) 5 µmol/
L or 500 nmol/L; CPT with caspase inhibitor Z-Val-Ala-
Asp-fluoromethyl ketone (ZVAD) from Calbiochem (San
Diego, CA) 50 µmol/L or ZVAD 50 µmol/L alone. After in-
cubation, media and cells were harvested for analysis.
In a study of MP-release in subconfluent, confluent and
overgrown HUVEC culture, the cells at 24 hrs (50% of
confluence), 48 hrs (reaching confluence) or 72 hrs (over-
grown) in culture were incubated for 24 hrs with 0.5 %
DMSO, 500 nM or 5 µM CPT in medium. After incubation
supernatant from cell culture was harvested and annexin
V-FITC-binding MP were counted.
In a study of expression of CD59 and CD105 on endothe-
lial cells, apoptotic bodies and other cell fragments, the
confluent HUVEC at 48 hrs in culture were treated for 24
hrs with 0.5% DMSO, 500 nM or 5 µM CPT in medium.
After treatment the cell culture supernatant was separated,
adherent cells were harvested with 20 mM HEPES buffer
with 100 mM NaCl, 0.5% BSA and 10 mM EDTA, pH 7.4,
and pooled with culture supernatant. This mixture of
cells, apoptotic bodies and other cell fragments was cen-
trifuged (300 g/5 min), washed with HBSS/BSA, labeled
in aliquots with saturating concentration of PE-conjugat-
ed Mab against CD105 or CD59, washed again in HBSS/
BSA and analyzed by flow cytometry.
Short-time stimulation of HUVEC
Confluent HUVEC were washed with HBSS and incubated
for 30 min at 37°C with various agonists in HBSS with
0.35%BSA: HBSS alone; 0.5 % dimethyl sulfoxide (DM-
SO); ionophore A23187 1–100 µmol/L; phorbol myr-
istate acetate (PMA) 1 µg/mL; human thrombin receptor
activating peptide SFLLRNP (TRAP) 1–50 µmol/L; human
thrombin (THR) US FDA standard lot J (Bethesda, MD)
0.1–10 NIH Unit/mL; human tissue plasminogen activa-
tor (TPA) 3.5 kU/mL or human angiotensin II (AGTII) 1
µmol/L. All chemicals were from Calbiochem (San Diego,
CA) unless otherwise stated. After incubation, cell cultures
were observed by phase contrast microscopy and cell su-
pernatants were collected for MP analysis.
Annexin V-labeling of microparticles
One hundred µL of medium or cell culture supernatant
were incubated with 4 µL of annexin V-FITC from BD
PharMingen (San Diego, CA) for 20 min at room temper-
ature with or without 50 mM EDTA to estimate the non-
specific binding. Fifty µL of labeled MP were added to Tru-
Count tubes (Becton Dickinson) containing standard
beads in 450 µL of HBSS/BSA solution. Samples were im-
mediately analyzed with flow cytometry.
Immunolabeling of annexin V-binding microparticles
Medium or cell supernatant containing MP were centri-
fuged at 2,700 g for 5 min, and the sediment was discard-
ed. Supernatant was further centrifuged at 19,800 g for 5
min at 10°C, and sedimented MP were resuspended in the
original volume of HBSS/BSA. Aliquots of 50 µL were in-
cubated for 20 min at room temperature with 2 µL of an-
nexin V-FITC from BD Pharmingen (San Diego, CA) and
saturating concentrations of PE-conjugated Mab. After in-
cubation and washing with 1 mL HBSS/BSA (centrifuged
at 19,800 g for 5 min at 10°C) samples were diluted with
450 µL HBSS/BSA and analyzed by flow cytometry.
Flow cytometry of endothelial cells and cell fragments
Cell samples were analyzed by a FACScan flow cytometer
(Becton Dickinson, San Diego, CA) equipped with CEL-BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/11
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LQUEST software with forward scatter (FSC) and side scat-
ter (SSC) in linear mode setting. Samples were analyzed
using forward scatter (FSC) vs. side scatter (SSC) plot and
propidium iodide (PI) fluorescence vs. FSC plot. Single
cells were gated separately in gate G1 and apoptotic bod-
ies and other cell fragment in gate G2 (Fig. 5). Count of
10,000 gated particles was analyzed for each sample. Ap-
optotic status of cells was assayed using Annexin V-FITC
Apoptosis Detection Kit for annexin V/ propidium iodide
cell labeling and using Apo-Direct Kit for terminal deoxy-
nucleotidyltransferase dUTP-FITC nick end labeling
(TUNEL) according to manufacturer's instruction (BD
Pharmingen, San Diego, CA). Percentages of propidium
iodide-negative cells binding annexin V and TUNEL-posi-
tive cells were evaluated. In a study of the expression of
CD59 and CD105 on HUVEC, histograms showing ex-
pression of CD105 and CD59 on cells (G1) and cell frag-
ments (G2) are presented. Binding of the IgG2a isotype
control (IgG-IC) corresponded to the fluorescence of non-
labeled cells and cell fragments. Standard Quantum TM24
beads (Flow Cytometry Standards, San Juan, PR) were run
each day as a separate sample to standardize fluorescence
readings.
Flow cytometry analysis of endothelial cell membrane mi-
croparticles
MP were analyzed in a separate protocol [3] using a mod-
ified method of Combes et al. [1]. Annexin V-FITC-posi-
tive MP were gated in a SSC vs. fluorescence logarithmic
plot. For MP quantitation, TruCount beads from Becton
Dickinson (San Diego, CA) were used in each sample as
an internal standard. TruCount beads were gated in a SSC
vs. FSC logarithmic plot and analysis was stopped when
5,000 beads were counted. MP count released by 103 cells
was calculated for each sample. TetraSpeck fluorescent mi-
crosphere standards of 0.2, 0.5, 1.0 and 4.0 µm in diame-
ter from Molecular Probes (Eugene, OR) were used to
estimate MP size based on comparison of FSC values. An-
tigen expression on MP was analyzed by double-labeling
with annexin V-FITC and PE-conjugated Mabs. The annex-
in V-FITC-positive MP were gated, and their binding of
PE-labeled Mabs was evaluated in SSC vs. PE – fluores-
cence logarithmic plots.
Abbreviations
AGTII, angiotensin II; BSA, bovine serum albumin; CHX,
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dothelial cells; IC-IgG, IgG isotype control; Mab, mono-
clonal antibody; MP, microparticles; PE, phycoerythrin;
PI, propidium iodide; PMA, phorbol-myristate-acetate;
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